Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Expects Guidance On Validating Device Development Tools To Speed Approvals

This article was originally published in The Gray Sheet

Executive Summary

A new FDA draft guidance establishes a voluntary process to validate publicly available device development tools so companies can routinely apply them to facilitate their path to market.

You may also be interested in...



Expanding The Medtech Toolbox: US FDA's 'Medical Device Development Tools' Program Rolls Out

Three years in the making, FDA has released a final guidance for medical device development tools that would allow developers to qualify their MDDTs and give medical device manufactures access to new tools that could help them prove safety and effectiveness of their products sooner.

Medical Device Innovation Consortium Advances Regulatory Science Projects

At the Regulatory Affairs Professionals Society annual meeting last week, William Hawkins, chairman of the Medical Device Innovation Consortium, said the group is making progress in its first project on computer modeling and simulation, as well as future projects on clinical trial reform, and benefit-risk guidance and patient-centeredness.

Medical Device Innovation Consortium Launches, Aims To Start Projects In 2013

The first public-private partnership to focus on promoting medical device regulatory science, known as the Medical Device Innovation Consortium, aims to speed up patient access to medical device technologies.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT032589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel